50 Moreover, the cytokines like TNF-��, IL-1�� and IL-6 are also associated with the remodeling process post-myocardial infarction.51 G-CSF plays a critical role in regulation selleck chemicals llc of proliferation, differentiation and survival of myeloid progenitor cells, mobilization of hemopoietic stem cells to the peripheral circulation and also stimulates healing and repair.52 EPO is important for erythrocyte survival and differentiation, vascular auto regulation and attenuation of apoptotic and inflammatory causes of cell death.53 The trafficking and survival of hematopoietic, endothelial progenitors and mesenchymal stem cells, augmentation of vasculogenesis, neovascularization in the ischemic tissues by the recruitment of endothelial progenitor cell (EPC), etc., are the major responsibilities of SDF-1.
54 The local functions of various cytokines are given in Table 2. Hyun-Jae Kang et al. conducted clinical studies on 116 human subjects with acute myocardial infarction with a combination of cell and cytokine therapy using erythropoietin analog, darbepoetin and G-CSF. Though these attempts are promising, more studies are needed to correlate the effect of cytokines onto the conventional therapeutic platforms.55 Table 2. Local functions of various cytokine-mediated therapy IGF-1 is responsible for nuclear phospho-Akt and telomerase activity and the delaying of cardiomyocyte aging and death.56 TNF-�� and IL-6 can attenuate myocyte contractility by the immediate reduction of systolic cytosolic (Ca2+) via alterations in sarcoplasmic reticulum function and is reversible by the removal of the cytokine signal.
57 However, TNF-�� can also downregulate myocyte contractility indirectly through nitric oxide-dependent attenuation of myofilament Ca2+ sensitivity.58 The remodeling signals mediated by cytokines and progenitor cells in the infarcted myocardium can also initiate the repair process which includes phagocytosis and resorption of the necrotic tissue, survival of the regenerating myocytes, degradation and synthesis of matrix, proliferation of the myofibroblasts, vasculogenesis and progenitor cell proliferation.59 Taken together, cytokine-mediated therapy is emerging to be a novel strategy for the management of end stage MI. The anti-cytokine therapeutic agents viz. p75 TNF receptor (Fc construct, etanercept, infliximab and adalimumab) are found to reduce the inflammatory risks of MI.
Certolizumab pegol is a novel TNF inhibitor which is having a comparatively high half life, since it is coupled to polyethylene glycol (PEG).60 Anti-TNF therapy was not fully successful. The main drawbacks found during clinical trials are toxicity, racial variations, polymorphism of TNF gene, adverse effects with other medications, etc. Moreover, patients with (NYHA) class III or IV heart failure AV-951 are not advised to treat with anti-TNF-�� medications. The same effect will occur with other cytokines also.